Sign in →

Test Code SP7TC Septin-7 Antibody, Tissue Immunofluorescence Titer, Spinal Fluid


Specimen Required


Only orderable as a reflex. For more information see:

-ENC2 / Encephalopathy, Autoimmune /Paraneoplastic Evaluation, Spinal Fluid

-MDC2 / Movement Disorder, Autoimmune /Paraneoplastic Evaluation, Spinal Fluid

-MAC1 / Autoimmune Myelopathy /Paraneoplastic Evaluation, Spinal Fluid 

 

Container/Tube: Sterile vial

Specimen Volume: 1.5 mL


Useful For

Detecting septin-7 IgG in cerebrospinal fluid (CSF) specimens

 

Reporting an end titer result from CSF specimens

Method Name

Only orderable as a reflex. For more information see:

-ENC2 / Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid

-MDC2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Spinal Fluid

-MAC1 / Autoimmune Myelopathy/Paraneoplastic Evaluation, Spinal Fluid

 

Indirect Immunofluorescence Assay (IFA)

Reporting Name

Septin-7 IFA Titer, CSF

Specimen Type

CSF

Specimen Minimum Volume

See Specimen Required

Specimen Stability Information

Specimen Type Temperature Time Special Container
CSF Refrigerated (preferred) 28 days
  Frozen  28 days
  Ambient  72 hours

Reject Due To

Gross hemolysis Reject
Gross lipemia Reject
Gross icterus Reject

Clinical Information

Neurological phenotypes for septin-7 IgG positive patients include encephalopathy, myelopathy, encephalomyelopathy, painful myelopolyradiculopathy, and episodic ataxia. Psychiatric symptoms are also common with encephalopathic symptoms. Septin-7 IgG is also associated with cancer and positive response to immunotherapy.

Reference Values

Only orderable as a reflex. For more information see:

-ENC2 / Encephalopathy, Autoimmune /Paraneoplastic Evaluation, Spinal Fluid

-MDC2 / Movement Disorder, Autoimmune /Paraneoplastic Evaluation, Spinal Fluid

-MAC1 / Autoimmune Myelopathy /Paraneoplastic Evaluation, Spinal Fluid

 

<1:2

Day(s) Performed

Monday through Sunday

Report Available

5 to 10 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

86256